HDM1002
As of the edition of 20 October 2026, HDM1002 is a drug known only by a code name: in active development; acts on GLP1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 11, 0 stopped early
- Disease areas
- Nutrition and metabolism; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 0 | 6 | 0 |
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 3 | 3 | 0 | 3 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hangzhou Zhongmei Huadong Pharmaceutical | Lead sponsor of trials | 2024 to now |